CEO, Novartis Oncology
Bruno Strigini has been CEO of Novartis Oncology since July 1, 2016. He is a member of the Executive Committee of Novartis. Mr. Strigini joined Novartis in 2014 as President of Oncology. Prior to Novartis, he was president of MSD for Europe and Canada (Merck & Co. in the United States and Canada). He previously worked at Schering-Plough, UCB Celltech and SmithKline Beecham, and his roles included president of international operations, president of Japan and Asia-Pacific, head of global marketing and business development, and managing director positions. Mr. Strigini holds a Master of Business Administration from IMD business school in Switzerland, a doctorate in pharmacy from the University of Montpellier in France, and a master’s degree in microbiology from Heriot-Watt University in the United Kingdom. He is an elected member of the French National Academy of Pharmacy, and in 2014, he was awarded a doctor honoris causa from Universidad Internacional Menéndez Pelayo in Spain.